Mold-Tek Packaging (533080) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
9 Sep, 2026Executive summary
Achieved 12% year-over-year revenue growth in FY25 to INR 781.32 crore, with sales volume up 7.3% to 38,264 MT and EBITDA up 6.98%, but PAT declined 9.05% due to higher depreciation and finance costs.
Q4 FY25 revenue rose 14.55% year-over-year to INR 202.61 crore, with EBITDA up 9.21% and PAT down 9.47%.
Pharma division crossed break-even in Q4, with turnover rising from INR 2.5 crores in Q3 to INR 6.7 crores in Q4, contributing INR 6.67 crore in FY25.
Paint segment reversed last year’s decline, posting 6.8% volume growth for the year.
Financial highlights
EBITDA per kg in Q4 reached INR 40.15, the highest in several quarters, while FY25 EBITDA per kg was INR 37.60.
Food and FMCG segment grew 25% in Q4 and 11.76% in FY25, aided by expanded printing capacity and new client additions.
Paint segment saw 13% value growth and 6.8% volume growth year-over-year.
IML and HTL labeled containers comprised 76% of total volume in Q4, up from 64.4% last year.
FY25 EPS declined 9.2% to 18.22; Q4 EPS fell 9% to 4.90.
Outlook and guidance
Pharma division expected to achieve INR 30+ crores turnover in FY26, with potential to reach INR 50 crores by FY27; capacity expansion and new product launches planned.
Paint segment targeted for double-digit growth, supported by capacity expansions and increased IML adoption.
Food and FMCG segment projected to grow 15–20% in FY26.
EBITDA per kg targeted to reach INR 42–43 in the next 1–2 years as high-margin pharma and FMCG contributions rise.
Latest events from Mold-Tek Packaging
- Sales and EBITDA rose, but net profit fell due to higher costs; capacity expansions underway.533080
Q2 24/25 - Q1 volumes and sales grew, but higher costs and new plant ramp-up impacted profitability.533080
Q1 24/25 - Q3 FY25 saw strong revenue and EBITDA growth, but PAT fell on higher costs; pharma and exports are rising.533080
Q3 24/25 - Q1FY26 saw 22% revenue growth and 35.5% profit rise, led by pharma and FMCG momentum.533080
Q1 25/26 - H1FY26 revenue up 16.05% and PAT up 24%, led by strong pharma and FMCG growth.533080
Q2 25/26 - EBITDA and PAT up nearly 20% YoY, led by pharma and FMCG growth, with strong outlook.533080
Q3 25/26 - EBITDA and PAT grew over 20% YoY, with robust Pharma and FMCG segment growth and strong FY27 outlook.533080
Q4 25/26 - Record revenue and profit growth led by pharma, food, and FMCG, with historic EBITDA per kg.533080
Q1 26/27